Mutation News and Research

RSS

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

Cancer Research UK to launch genetic testing programme

Cancer Research UK's chief executive Harpal Kumar today spoke of a 'golden era' for cancer research as the UK is poised to lead the world in individualising the practice of medicine by understanding which treatments are best suited to an individual patient's particular genetic type of cancer.

16 Jun 2011

Potential new drug therapies targeting genetic mutations benefit lung-cancer patients

Some lung-cancer patients at UT Southwestern Medical Center are responding well to potential new drug therapies targeting genetic mutations. Their participation in a national study is helping to forge new avenues to attack the disease.

16 Jun 2011

Life Technologies introduces CytoTune-iPS Reprogramming Kit

Life Technologies Corporation today announced the launch of CytoTune-iPS Reprogramming Kit -- research technology that provides far improved efficiency over standard methods to develop induced pluripotent stem cells from human somatic cells.

16 Jun 2011

Exposure to asbestos can cause genetic somatic mutations in mammals

Mice inhabiting an area known for its high concentration of asbestos-contaminated dust, have a higher level of genetic somatic mutations, compared with other regions where asbestos pollution levels are lower.

16 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

A type of virus known as the human reovirus possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation, while leaving the body's normal cells alone.

15 Jun 2011

Calcium-sensing receptor plays key role in lethal lung cancer complication

A protein previously thought not to exist in adult human lungs not only is present in normal and cancerous lung tissue, scientists have found, but it also has a major role in the development of a lethal complication of some lung cancers.

14 Jun 2011

JEM published paper identifies new gene mutations in patients with chronic lymphocytic leukemia

A paper published online on June 13 in the Journal of Experimental Medicine identifies new gene mutations in patients with chronic lymphocytic leukemia (CLL)—a disease often associated with lack of response to chemotherapy and poor overall survival.

14 Jun 2011

Scientists identify six influenza A viruses similar to 2009 pandemic strain

Scientists using new mathematical and computational techniques have identified six influenza A viruses that have particularly close genetic relationships to the H1N1 "swine" flu virus that swept through the United States beginning in the spring of 2009. That virus eventually killed almost 18,000 people worldwide.

14 Jun 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.

14 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

Each one of us receives 60 new mutations in our genome from parents

Each one of us receives approximately 60 new mutations in our genome from our parents. This striking value is reported in the first-ever direct measure of new mutations coming from mother and father in whole human genomes published today.

13 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

Study links mutations in essential genes with orphan diseases

Mutations in genes essential to survival are behind so-called orphan diseases, explaining in part why these diseases are rare and often deadly, according to a study appearing in The American Journal of Human Genetics.

10 Jun 2011

Research provides better understanding of interplay between genomes of malaria parasites, humans

For tens of thousands of years, the genomes of malaria parasites and humans have been at war with one another. Now, University of Pennsylvania geneticists, in collaboration with an international team of scientists, have developed a new picture of one way that the human genome has fought back.

10 Jun 2011

NKI, Agendia and MD Anderson collaborate for colorectal cancer research

Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center, one of the world's leading cancer centers and whose research program is considered one of the most productive in the world aimed solely at cancer, and the Netherlands Cancer Institute (NKI) with the aim of improving diagnosis and treatment options of colorectal cancer patients.

10 Jun 2011

NIH awards $1.9M grant to Scripps Research scientist for malaria study

A scientist from The Scripps Research Institute has won a four-year, $1.9 million grant from the National Institutes of Health to better understand the parasite that causes malaria, laying the groundwork to develop better drugs to combat the widespread and deadly disease.

10 Jun 2011

Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Synaptophysin controls replacement of vesicles

A University of Wisconsin-Madison research team has solved a 25-year mystery that may lead to better treatments for people with learning deficits and mental retardation.

9 Jun 2011